Diabetes and metabolic health Archive

Continuous glucose monitors, or CGMs, offer valuable and accurate insights into blood sugar levels. But it's important to understand who CGMs are most appropriate for.

Implantable blood sugar monitoring devices known as CGMs have revolutionized care for millions of people with diabetes. Now several companies are marketing them for people without diabetes to monitor blood sugar levels -- but is there any evidence for health benefits?

Metformin, a medicine prescribed to treat type 2 diabetes, also has cardiovascular benefits and is used off-label to treat other conditions. Interest is growing in its potential to help lower risks for other serious health problems and even slow aspects of aging, but which of these benefits, if any, apply to people who do not have diabetes?

Standard definitions consider a healthy body mass index (BMI), a calculation based on a person's height and weight, as between 18.5 and 24.9. Studies have found that a higher BMI increases risk for heart disease, diabetes, and some types of cancer. However, even if their BMI does not fall into the category of overweight, people who gain five or more pounds may be at risk for health problems, especially if the weight gain is belly fat. The best approach is a combination of aerobic exercise, strength training, and a healthy diet.

People who lose weight with a portion-controlled diet and exercise may be able to reverse their diabetes. When that happens, their risk of heart disease and kidney disease declines, according to a 2024 study.

A 2023 study suggests that women who prefer to stay up and wake up later are more likely to develop diabetes and to have unhealthful lifestyle habits compared with those who prefer to go to bed and wake up earlier.

A 2023 study suggests that having diabetes may be tied to a higher risk of developing colorectal cancer than not having diabetes.

The weight-loss drug semaglutide is the first obesity treatment shown to help people live longer and have fewer cardiovascular problems. Developed as a drug for type 2 diabetes, semaglutide was first marketed as Ozempic; a higher-dose version for weight loss is called Wegovy. But because the drug is so popular, it can be hard to find, and it might not be covered by insurance.